Immunological effects of nivolumab immunotherapy in patients with oral cavity squamous cell carcinoma

• Published in: BMC cancer 2020-03, Vol.20 (1), p.229-229, Article 229
• Main Authors: Xiong, Ying, Neskey, David M, Horton, Joshua D, Paulos, Chrystal M, Knochelmann, Hannah M, Armeson, Kent E, Young, M Rita I
• Format: Article
• Language: English
• Subjects: Aged; Analysis; Anti-PD-1 antibody; Antibodies; Antineoplastic Agents, Immunological - therapeutic use; Biological response modifiers; Cancer therapies; Cancer vaccines; Carcinoma; Carcinoma, Squamous Cell - drug therapy; Carcinoma, Squamous Cell - immunology; Care and treatment; CD4; CD4-Positive T-Lymphocytes - immunology; CD8; CD8-Positive T-Lymphocytes - immunology; Cytokines; Female; Granzyme B; Humans; Immune; Immunoglobulins; Immunology; Immunotherapy; Interferon; Interferon-γ; Male; Melanoma; Metastasis; Middle Aged; Monoclonal antibodies; Mouth Neoplasms - drug therapy; Mouth Neoplasms - immunology; Nivolumab; Nivolumab - therapeutic use; Oral cavity; Patients; Pembrolizumab; Squamous cell carcinoma; T cells; T-Lymphocytes, Regulatory - immunology; Targeted cancer therapy; Thyroid gland
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-020-06726-3

Although checkpoint blockades have become widely used, the immunological impact in cancer patients, especially those with oral cavity squamous cell carcinoma (OCSCC), has not been well studied. The present study assessed the immunological impact of anti-PD-1 (nivolumab) treatment in 10 patients with OCSCC. This involved phenotypic analyses of peripheral blood T-cell subpopulations and their expression of immune mediators prior to and following nivolumab treatment. The focus was on immunological effects of treatment without regard to possible clinical responses. Nivolumab caused a decline in the frequency of blood CD4 cells but did not affect their expression of IFN-γ. However, nivolumab increased the proportion of CD4 cells expressing the Treg-supporting factor Foxp3. Nivolumab treatment caused an increase in the proportion of CD8 cells. While their expression of granzyme B increased, it did not attain significance. Analyses of CD8 cell subpopulations showed nivolumab caused an increase in levels of unconventional CD8 CD3 T-cells. It also caused an increase in expression of granzyme B by these unconventional T-cells as well as by the conventional CD8 CD3 cells. The CD8 CD3 subpopulation also had a near-significant increase in IFN-γ expression. Treatment with nivolumab had no effect on the levels of the NK containing CD8 CD3 subpopulation of cells or their expression of IFN-γ or granzyme B. These results show nivolumab causes opposing effects on CD4 and CD8 cell populations, with CD4 cell levels declining but increasing the proportion of Treg cells, and unconventional CD8 T-cell levels increasing with increased expression of immune mediators by CD8 T-cell subpopulations.